Sign In
Buy DXCM
$82.66
-4.28 (-4.92%)
At Close: Aug 05, 2026
2 Stocks That Turned $40,000 Into $1 Million in 10 Years
09:45am, Thursday, 13'th Apr 2023
DexCom and Tesla have become profitable in recent years as their sales have soared. The two are focused on growing industries -- diabetes care and electric vehicles.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
09:09am, Thursday, 13'th Apr 2023
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
A Nasdaq Bull Market Is Coming: 2 Fantastic Stocks to Buy and Hold
09:45am, Saturday, 08'th Apr 2023
History shows that patient investors can reap rewards by consistently putting money to work. DexCom controls a notable slice of the diabetes care industry and is raking in profits.
3 No-Brainer Medical Device Stocks to Buy Right Now
07:45am, Thursday, 06'th Apr 2023
Edwards Lifesciences' state-of-the-art heart valves have a big growth runway. Abbott Laboratories has received several encouraging FDA approvals recently.
Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
05:30am, Thursday, 06'th Apr 2023
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will
2 Explosive Growth Stocks to Buy in April
09:08am, Wednesday, 05'th Apr 2023
Not all growth-oriented businesses are created equal, and some are continuing to thrive even now. DexCom is reaching more and more users than ever, but its addressable, untapped market opportunity is
2 All-Weather Stocks to Buy Without Hesitation Right Now
08:45am, Friday, 31'st Mar 2023
While high inflation is pressuring the market, many healthcare businesses remain resilient. DexCom has a long runway for growth as the need for diabetes treatment expands.
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
02:12pm, Thursday, 30'th Mar 2023
Les Funtleyder, portfolio manager for E Squared Capital Management, joins 'The Exchange' to discuss big cap pharma's Q1 performance, the dollar weakness contributing to biotech gains, and investment o
Where Will DexCom Be in 1 Year?
07:45am, Wednesday, 29'th Mar 2023
DexCom plans to keep rolling out key new devices in the next year. The company should continue growing its revenue and installed base.
11 stocks in the S&P 500 expected to form an exclusive growth club for investors
08:10am, Monday, 27'th Mar 2023
Following an 18% decline for the S&P 500 index (with dividends reinvested) in 2022 and a volatile and disappointing pullback from this year's stock-market rebound that crested early in February, some
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
05:41am, Saturday, 25'th Mar 2023
The Nasdaq Composite index has been down for over a year now, but some of its components are soaring. Vertex Pharmaceuticals is the only drugmaker selling lifesaving treatments for patients who inheri
Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada
01:45pm, Friday, 24'th Mar 2023
Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.
Dexcom Stock Option Trade Could Return $465 While Risking Just $35
12:10pm, Friday, 24'th Mar 2023
Still caught in a wide performance range, it is beginning to show signs of price improvement. The post Dexcom Stock Option Trade Could Return $465 While Risking Just $35 appeared first on Investor's B
DexCom: Riding The Growth Wave
06:32pm, Wednesday, 15'th Mar 2023
DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the o
Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify
08:21pm, Sunday, 12'th Mar 2023
Silicon Valley Bank required some clients to agree to exclusivity clauses, disabling them from diversifying where they held their money, SEC records show.
